Rezivertinib Mesylate

甲磺酸瑞齐替尼

Report date: 2025/11/21 16:24:18
NME

Base Information

Drug NameRezivertinib Mesylate
Drug Alias NameRezivertinib mesylate甲磺酸瑞泽替尼瑞泽替尼Rezivertinib瑞必达 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitors
TargetsEGFR T790M
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2024/05/15
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeta Pharma Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCSPC Pharmaceutical Group LtdBetapharma (Shanghai) Co Ltd
Inactive CompaniesBeta Pharma Inc
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A